William Blair initiates Edgewise Therapeutics stock with outperform rating

William Blair initiated coverage on Edgewise Therapeutics (EWTX) with an outperform rating and a $53 price target. The stock is up 149% over the past year, trading at $38.20. The company has $2B in cash and focuses on cardiovascular disease treatments, with key catalysts expected in 2026-2027. H.C. Wainwright reiterated its Buy rating with a $57 target.

Original reporting
Published Oct 16, 2026, 7:36 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 7:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$EWTX
Bullish
high confidence
Mentioned
$EWTX
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$EWTXBullishMed
01

Why it matters

Analyst coverage adds credibility and may attract new capital, but trial outcomes remain uncertain.

02

Market read

The initiation provides a fresh catalyst for EWTX, potentially influencing short-term price action.

03

What to watch

Potential regulatory delays and cash burn from multiple Phase II/III programs could temper upside.

Relevance 7/10Novelty 6/10Timing: today

Background

Edgewise Therapeutics recently sold its Sevasemten business to Servier and is refocusing on cardiovascular candidates.

Company-level read

Ticker impact

$EWTXBullishHigh confidence
Context

William Blair initiated coverage on Edgewise Therapeutics with an outperform rating and a $53 DCF valuation, highlighting recent $1.55B asset sale and upcoming Phase III trial start.

Expected impact

likely upward pressure as investors price in the new target and pipeline catalysts

Evidence & confidence

Coverage initiation is a fresh catalyst; valuation above current price suggests upside potential.

Market effects

Positive signal for the cardiac biotech subsector as a peer receives a favorable analyst rating.

Limited to US biotech investors; no broader regional effect.

Minimal global impact beyond niche biotech investors.

Counterpoint

The valuation may be overly optimistic given early-stage trial risk and recent asset divestiture.

Key entities

  • Edgewise Therapeutics

    NASDAQ-listed biotech developing cardiac sarcomere modulators.

  • William Blair

    Investment bank that initiated coverage with an outperform rating.

Related articles

$EWTXMed

Raymond James raises Edgewise Therapeutics price target on FDA feedback

Raymond James raised its price target on Edgewise Therapeutics (EWTX) to $85 from $66, maintaining a Strong Buy rating. This follows FDA feedback on EDG-7500 for hypertrophic cardiomyopathy. EWTX stock is up 116% over the past year and 51% year-to-date, trading at $38.90. The company recently sold its muscular dystrophy business for $1.55 billion, focusing on cardiovascular disease. Analysts William Blair and H.C. Wainwright also issued positive ratings and targets.

$EWTXMed

Edgewise submits phase 3 protocol for heart drug EDG-7500

Edgewise Therapeutics (EWTX) submitted a Phase 3 protocol for EDG-7500, a drug for hypertrophic cardiomyopathy, to the FDA. The STRATUS-HCM trial will include 600 adults, with primary endpoint being change in peak oxygen consumption after 24 weeks. The company plans to start the trial in Q4 2026, with consistent feedback from global regulators.

$EWTXMedAI 8/10

Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring

Edgewise Therapeutics (EWTX) received positive FDA feedback on its EDG-7500 drug for hypertrophic cardiomyopathy (HCM). The Phase 3 trial, STRATUS-HCM, will start in Q4 2026, featuring a tolerability-based dose escalation plan without echo monitoring. The trial aims to enroll 600 adults with symptomatic HCM, with peak VO₂ as the primary endpoint.

$EWTXHigh

Edgewise Therapeutics Reports Third Quarter 2026 Financial Results

Edgewise Therapeutics, Inc. (EWTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 News Release Edgewise Therapeutics Reports Third Quarter 2026 Financial Results – Published the differentiated mechanism of action of EDG-7500 that targets the regulatory light chain – – Phase 3 trial for EDG-7500 in obstructive and nonobstructive hypertrophic cardio